|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Moexipril#Adverse Reactions]] |
| {{Moexipril}}
| |
| {{CMG}}; {{AE}} {{AM}}
| |
| | |
| ==Adverse Reactions==
| |
| | |
| Moexipril hydrochloride has been evaluated for safety in more than 2500 patients with hypertension; more than 250 of these patients were treated for approximately one year. The overall incidence of reported adverse events was only slightly greater in patients treated with moexipril hydrochloride than patients treated with placebo.
| |
| | |
| Reported adverse experiences were usually mild and transient, and there were no differences in adverse reaction rates related to gender, race, age, duration of therapy, or total daily dosage within the range of 3.75 mg to 60 mg. Discontinuation of therapy because of adverse experiences was required in 3.4% of patients treated with moexipril hydrochloride and in 1.8% of patients treated with placebo. The most common reasons for discontinuation in patients treated with moexipril hydrochloride were cough (0.7%) and dizziness (0.4%).
| |
| | |
| All adverse experiences considered at least possibly related to treatment that occurred at any dose in placebo-controlled trials of once-daily dosing in more than 1% of patients treated with moexipril hydrochloride alone and that were at least as frequent in the moexipril hydrochloride group as in the placebo group are shown in the following table:
| |
| {|
| |
| | [[File:b14.png|800px|thumb]]
| |
| |}
| |
| Other adverse events occurring in more than 1% of patients on moexipril that were at least as frequent on placebo include: [[headache]], upper respiratory infection, pain, [[rhinitis]], [[dyspepsia]], [[nausea]], [[peripheral edema]], [[sinusitis]], [[chest pain]], and urinary frequency. [[Angioedema]], [[hypotension]], [[neutropenia]]/[[agranulocytosis]], second and third trimester fetal/neonatal morbidity and mortality, [[hyperkalemia]], and [[cough]].
| |
| | |
| Other potentially important adverse experiences reported in controlled or uncontrolled clinical trials in less than 1% of moexipril patients or that have been attributed to other ACE inhibitors include the following:
| |
| | |
| ====Cardiovascular====
| |
| | |
| Symptomatic [[hypotension]], [[postural hypotension]], or [[syncope]] were seen in 9/1750 (0.51%) patients; these reactions led to discontinuation of therapy in controlled trials in 3/1254 (0.24%) patients who had received moexipril hydrochloride monotherapy and in 1/344 (0.3%) patients who had received moexipril hydrochloride with hydrochlorothiazide. Other adverse events included [[angina]]/[[myocardial infarction]], [[palpitations]], [[rhythm disturbances]], and [[cerebrovascular accident]].
| |
| | |
| ====Renal====
| |
| | |
| Of hypertensive patients with no apparent preexisting renal disease, 1% of patients receiving moexipril hydrochloride alone and 2% of patients receiving moexipril hydrochloride with hydrochlorothiazide experienced increases in [[serum creatinine]] to at least 140% of their baseline values.
| |
| | |
| ====Gastrointestinal====
| |
| | |
| [[Abdominal pain]], [[constipation]], [[vomiting]], appetite/weight change, dry mouth, [[pancreatitis]], [[hepatitis]].
| |
| | |
| ====Respiratory====
| |
| | |
| [[Bronchospasm]], [[dyspnea]], [[eosinophilic pneumonitis]].
| |
| | |
| ====Urogenital====
| |
| | |
| [[Renal insufficiency]], [[oliguria]].
| |
| | |
| ====Dermatologic====
| |
| | |
| Apparent hypersensitivity reactions manifested by [[urticaria]], [[rash]], [[pemphigus]], [[pruritus]], [[photosensitivity]], [[alopecia]].
| |
| | |
| ====Neurological and Psychiatric====
| |
| | |
| [[Drowsiness]], [[sleep disturbances]], [[nervousness]], [[mood changes]], [[anxiety]].
| |
| | |
| ====Other====
| |
| | |
| [[Angioedema]] , taste disturbances, [[tinnitus]], sweating, [[malaise]], [[arthralgia]], [[hemolytic anemia]].
| |
| | |
| ====Clinical Laboratory Test Findings====
| |
| | |
| ====Serum Electrolytes====
| |
| | |
| [[Hyperkalemia]] , [[hyponatremia]].
| |
| | |
| ====Creatinine and Blood Urea Nitrogen====
| |
| | |
| As with other ACE inhibitors, minor increases in blood urea nitrogen or [[serum creatinine]], reversible upon discontinuation of therapy, were observed in approximately 1% of patients with essential hypertension who were treated with moexipril hydrochloride. Increases are more likely to occur in patients receiving concomitant diuretics and in patients with compromised renal function.
| |
| | |
| ====Other====
| |
| | |
| Clinically important changes in standard laboratory tests were rarely associated with moexipril hydrochloride administration.
| |
| | |
| Elevations of liver enzymes and uric acid have been reported. In trials, less than 1% of moexipril-treated patients discontinued moexipril hydrochloride treatment because of laboratory abnormalities. The incidence of abnormal laboratory values with moexipril was similar to that in the placebo-treated group.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MOEXIPRIL HYDROCHLORIDE TABLET [APOTEX CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d18108f5-98ca-1220-d145-bcf4e71ceaee | publisher = | date = | accessdate = }}</ref>
| |
| | |
| | |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |